您好,欢迎您

2023 ESMO | 星火成炬,LBA中国之声总数创新高!

2023年09月28日
整理:肿瘤资讯
来源:肿瘤资讯

欧洲中部夏令时间2023年9月28日,欧洲内科肿瘤学会(ESMO)公布了即将召开的2023年ESMO大会上最为重磅的摘要LBAs(Late- Breaking Abstracts)题目及信息,覆盖Presidential Symposium(主席大会)、Proffered Paper Session(优选论文会议)、Mini Oral Session(简短口头摘要会议)所有口头摘要公布的会议。
 
据【肿瘤资讯】统计,今年中国研究入选LBAs总数高达14项,研究入选专家高达12位,远超2022年的7项研究6位专家,达到历史新高!其中,北京大学肿瘤医院张小田教授复旦大学附属肿瘤医院吴小华教授各有两项研究入选LBAs。详情请看下文(以下按照摘要号进行排序)!

LBA4 - Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC

讲者:中国香港 香港中文大学 龙浩锋教授(Herbert Ho Fung Loong)

LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)

讲者:中国武汉 华中科技大学同济医学院附属协和医院 林振宇教授
 
LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial

讲者:中国广州 中山大学肿瘤防治中心 丁培荣教授
 
LBA33 - A first-in-human phase 1 study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation

讲者:中国上海 上海市肺科医院 周彩存教授
 
LBA36 - Efficacy and Safety of Senaparib as Maintenance Treatment in Patients with Newly Diagnosed Advanced Ovarian Cancer (FLAMES Study): A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

讲者:中国上海 复旦大学附属肿瘤医院 吴小华教授
 
LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer

讲者:中国上海 复旦大学附属肿瘤医院 吴小华教授
 
LBA58 - Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-IIIA NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial

讲者:中国天津 天津医科大学肿瘤医院 岳东升教授
 
LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer

讲者:中国广州 中山大学肿瘤防治中心 赵泽锐教授
 
LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): a randomized multicenter study

讲者:中国北京 中国人民解放军总医院 胡毅 教授  
 
LBA78 - Overall Survival of Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy: An Updated Analysis of RESOLVE Trial

讲者:中国北京 北京大学肿瘤医院 张小田教授
 
LBA79 - GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase 3 study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

讲者:中国北京 北京大学肿瘤医院 张小田教授 
 
LBA80 - Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Final Analysis Results of the RATIONALE-305 Study

讲者:中国广州 中山大学肿瘤防治中心 徐瑞华教授

LBA93 - EXTENTORCH: a randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)

讲者:中国长春 吉林省肿瘤医院 柳影教授

LBA96 - Roxadustat for Chemotherapy-Induced Anemia in Patients with Non-Myeloid Malignancies: A Randomized, Open-Label, Active-Controlled, Phase III Study

讲者:中国上海 上海市胸科医院 陆舜教授


 
2022年ESMO LBAs中国研究入选情况详见:2022 ESMO大会 | LBA之中国之声,医疗界顶级专家学者分享最新研究与实践!


(LBAs信息公布持续进行中,如有遗漏欢迎补充!)
 

参考文献

https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session


责任编辑:肿瘤资讯-Bree
排版编辑:肿瘤资讯-Bree
               
版权声明
本文专供医学专业人士参考,未经著作人许可,不可出版发行。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。